Postoperative Fasting Blood Glucose Predicts Prognosis in Stage I-III Colorectal Cancer Patients Undergoing Resection.
Journal
Gastroenterology research and practice
ISSN: 1687-6121
Titre abrégé: Gastroenterol Res Pract
Pays: Egypt
ID NLM: 101475557
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
10
2019
revised:
25
12
2019
accepted:
28
12
2019
entrez:
9
5
2020
pubmed:
10
5
2020
medline:
10
5
2020
Statut:
epublish
Résumé
The relationship between high blood glucose and colorectal cancer (CRC) has been studied, but the role of postoperative fasting blood glucose (FBG) in patients with a prior normal FBG has never been addressed. A total of 120 CRC patients staged I-III were enrolled, and the prognostic value of postoperative FBG for disease-free survival (DFS) was determined by Kaplan-Meier analysis. Univariate and multivariate analyses were conducted to test other clinicopathological parameters, including preoperative hemoglobin (HGB) and the neutrophil-lymphocyte ratio (NLR). By a cut-off point of 5.11 mmol/L, 51 and 69 patients were divided into low postoperative FBG (<5.11 mmol/L) and high postoperative FBG (≥5.11 mmol/L) groups, respectively. A high postoperative FBG was more common in older age ( Postoperative FBG plays a temporal prognostic role for patients with stage I-III CRC with a prior normal FBG, but it is not an independent prognostic factor.
Identifiants
pubmed: 32382263
doi: 10.1155/2020/2482409
pmc: PMC7199537
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2482409Informations de copyright
Copyright © 2020 Rui Xu et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Cell Cycle. 2013 Dec 15;12(24):3759-69
pubmed: 24107633
Eur J Cancer. 2019 Apr;111:1-7
pubmed: 30797014
Scand J Gastroenterol. 2006 Sep;41(9):1079-86
pubmed: 16938722
Breast Cancer Res Treat. 2013 Apr;138(3):951-9
pubmed: 23568483
Korean J Fam Med. 2018 Jan;39(1):42-50
pubmed: 29383211
Med Sci Monit. 2015 Dec 08;21:3825-33
pubmed: 26644185
Lung Cancer. 2012 May;76(2):242-7
pubmed: 22112292
Br J Cancer. 2017 Oct 24;117(9):1405-1411
pubmed: 28873085
Cell Biochem Funct. 2009 Mar;27(2):93-101
pubmed: 19205005
BMC Gastroenterol. 2016 Dec 21;16(1):142
pubmed: 28003023
Gerontology. 2011;57(6):497-501
pubmed: 21411967
Nat Genet. 2019 Jul;51(7):1113-1122
pubmed: 31209394
Medicine (Baltimore). 2014 Nov;93(23):e135
pubmed: 25415667
Oncoimmunology. 2017 Dec 21;7(3):e1356144
pubmed: 29399387
BMC Cancer. 2018 Feb 6;18(1):151
pubmed: 29409475
Mutat Res. 2013 May 15;753(2):76-81
pubmed: 23422045
J Clin Oncol. 2005 Dec 1;23(34):8664-70
pubmed: 16260700
Eur J Gastroenterol Hepatol. 2004 Jun;16(6):593-8
pubmed: 15167162
Am J Gastroenterol. 2009 Sep;104(9):2318-25
pubmed: 19513024
Am J Epidemiol. 2004 Jun 15;159(12):1160-7
pubmed: 15191933
Br J Surg. 1993 Aug;80(8):1047-50
pubmed: 8402064
ScientificWorldJournal. 2012;2012:696329
pubmed: 23125556
Diabetes Technol Ther. 2014 Aug;16(8):524-30
pubmed: 24455985
Oncotarget. 2016 Oct 4;7(40):65247-65256
pubmed: 27533454
Nat Rev Cancer. 2016 Oct;16(10):635-49
pubmed: 27634447
Ann Surg Oncol. 2018 Feb;25(2):431-438
pubmed: 29181680
Future Oncol. 2019 May;15(15):1745-1758
pubmed: 31038364
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
JAMA. 2005 Jan 12;293(2):194-202
pubmed: 15644546
World J Gastroenterol. 2016 Jul 21;22(27):6235-45
pubmed: 27468213
Cancer Manag Res. 2019 Apr 16;11:3265-3274
pubmed: 31114364
Int J Oncol. 2014 Jun;44(6):2077-84
pubmed: 24718784
Arch Intern Med. 2000 Jul 24;160(14):2217
pubmed: 10904467
Onco Targets Ther. 2019 Jul 23;12:5947-5953
pubmed: 31413592
Future Oncol. 2018 May;14(12):1187-1196
pubmed: 29302993